Triple Hair Group Initiates Phase III Trial of TH07 for Male Pattern Hair Loss in India 

Key Highlights:  

• Triple Hair Group announced the initiation of a Phase III clinical trial in India evaluating TH07, the company’s patented prescription topical therapy for male androgenic alopecia 

• The India study is expected to enroll 500 male patients and forms part of Triple Hair’s broader international late-stage development strategy for TH07. Combined with the ongoing Canadian Phase III study, the coordinated program is expected to evaluate the therapy in ~920 patients under a harmonized clinical development framework designed to support global regulatory and commercialization efforts 

• Triple Hair Group is conducting the study with clinical and manufacturing partners in Canada and India, including Akums, as the company advances TH07 as a potential late-stage treatment option for androgenic alopecia across major international markets 

Implications: 

Triple Hair is turning TH07 into a genuinely global late‑stage asset in male pattern hair loss by running synchronized Phase III trials in Canada and India that together will follow close to 1,000 men. 

By teaming with local partners like Akums and using a harmonized trial design, the company is building a single, robust data package meant to support regulatory filings and partnering discussions in multiple major markets, positioning its triple‑combination topical (minoxidil, finasteride, latanoprost) as a potential higher‑efficacy alternative to today’s standard monotherapies. 

Source: Triple Hair Group